Electrostimulation Study for Ocular Graft vs. Host Disease

NCT ID: NCT07166848

Last Updated: 2025-12-17

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Clinical Phase

NA

Total Enrollment

15 participants

Study Classification

INTERVENTIONAL

Study Start Date

2025-11-30

Study Completion Date

2029-11-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This trial is testing to see if electrostimulation treatment (ET) will be effective in treating those with ocular Graft vs. Host Disease.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The trial is to test whether transcutaneous electrical stimulation (TES) may be an effective new type of non-invasive treatment for patients who are diagnosed with chronic ocular Graft-vs-Host Disease. Such a treatment can potentially decrease the need for the patients to apply eye drops frequently, repair the damage caused by chronic ocular Graft-vs-Host Disease, and improve the comfort of the eyes naturally.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Chronic Ocular Graft-versus-host Disease

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

DOUBLE

Participants Investigators
The principal investigator and the participants will be masked to treatment. The study staff setting up the device will be the only staff who will know the randomization.

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Electrostimulation

The experimental group will entail the subject wearing the electrodes on the cheeks and forehead, for 30 minutes WITH amplitude.

Group Type EXPERIMENTAL

Electrodes with Currents

Intervention Type DEVICE

Electrodes will be placed on the cheeks and forehead, and treated with an amplitude of 300 µA for 30 mins

Sham

The placebo group will entail the subject wearing the electrodes on the cheeks and forehead, for 30 minutes WITHOUT amplitude.

Group Type SHAM_COMPARATOR

Electrodes without Currents

Intervention Type DEVICE

Electrodes will be placed on the cheeks and forehead, and treated with an no amplitude for 30 mins

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Electrodes with Currents

Electrodes will be placed on the cheeks and forehead, and treated with an amplitude of 300 µA for 30 mins

Intervention Type DEVICE

Electrodes without Currents

Electrodes will be placed on the cheeks and forehead, and treated with an no amplitude for 30 mins

Intervention Type DEVICE

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Treatment Sham

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Diagnosis of chronic ocular graft vs. host disease (oGVHD) (ICCGVHD criteria probable or definite)
* OSDI score of 22 or higher
* NEI corneal staining score (or modified NEI score) of 2 or higher.

Exclusion Criteria

* Patients with any open wound on the eyelid.
* Patient with any active cornea ulcer, dacryocystitis, hordeolum, filamentary keratitis, uveitis, retinal detachment, uncontrolled glaucoma or other active pathology per PI's discretion.
* Patient with a pacemaker or ICD.
* Patient currently pregnant or with a potential to be pregnant during the study.
* Patient undergoing any ocular surgical procedure (including intravitreal injections) within the past 3 months.
* Patient undergoing any systemic surgical procedures within 2 months.
* Patient undergoing any non-surgical eyelid procedure such as punctal plugs or punctal cautery within 1 month of study initiation.
* Patients on cytotoxic agents, drugs that inhibit peripheral nerve regeneration (i.e. Gabapentin, Nicotine), radiation therapy, or any other therapy per PI's discretion.
* Patients undergoing immunosuppression regimen change within 1 month of study initiation and/or during the study period.
* Patient who wears contact lens of any kind
Minimum Eligible Age

18 Years

Maximum Eligible Age

75 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Zhonghui K. Luo, MD, PhD

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Zhonghui K. Luo, MD, PhD

Principal Investigator

Responsibility Role SPONSOR_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Zhonghui Luo, MD, PhD

Role: PRINCIPAL_INVESTIGATOR

Massachusetts Eye and Ear Infirmary

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Massachusetts Eye and Ear - Longwood Campus

Boston, Massachusetts, United States

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

United States

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Michael Cheung, MSc, CCRP

Role: CONTACT

6175736060

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Michael Cheung, MSc, CCRP

Role: primary

617-573-6060

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

2025P002105

Identifier Type: -

Identifier Source: org_study_id